|
| |
CHEMOCENTRYX. Pages on BioPortfolio:
BioPortfolio - ChemoCentryx, Inc.
16 Oct 2008 ... ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
BioPortfolio - BioPortfolio - ChemoCentryx
BioPortfolio - ChemoCentryx - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/linkout/2673/www.ch...
|
BioPortfolio - ChemoCentryx, Inc. - Profile
View the current ChemoCentryx, Inc. Page on BioPortfolio.com ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available ...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
BioPortfolio - amgen chemocentryx
amgen chemocentryx - BioPortfolio. ... Recent Search Terms used to find this page: amgen chemocentryx | chemocentryx . ...
http://www.bioportfolio.com/search/amgen_chemocentryx.html...
|
Solexa Names Linda Rubinstein Vice President And CFO
Among her responsibilities at ChemoCentryx, she served on the executive and ... Prior to joining ChemoCentryx, Ms. Rubinstein was senior vice president in ...
http://www.bioportfolio.com/news/solexa_12.htm...
|
BioPortfolio - Biocorporate Search Inflammation1
ChemoCentryx is a privately held biopharma company specializing in the biology of chemokines, protein hormones that regulate the migration, or trafficking, ...
http://www.bioportfolio.com/biocorporate/Inflammation-compan...
|
BioPortfolio - CCR2
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, ...
http://www.bioportfolio.com/indepth/CCR2.html...
|
BioPortfolio - Biocorporate Search Digestive1
ChemoCentryx is a focused pharmaceutical company creating first-in-class, ... By leveraging our pioneering... www.chemocentryx.com/ View full profile ...
http://www.bioportfolio.com/biocorporate/Digestive-companies...
|
BioPortfolio - CXCR3
16 Oct 2008 ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available ... www.chemocentryx.com/ View full profile ...
http://www.bioportfolio.com/indepth/CXCR3.html...
|
BioPortfolio - CCR9 - chemokine (C-C motif) receptor 9
ChemoCentryx initiates Phase I gastrointestinal diseases trial ... ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical ...
http://www.bioportfolio.com/gene/10803-CCR9.html...
|
Results from other life science and pharmaceutical sites:
BioSpace - ChemoCentryx, Inc. News, Search Jobs, Events
ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for
...
http://www.biospace.com/company_profile.aspx?CompanyId=13520...
|
GlaxoSmithKline and ChemoCentryx enter into drug discovery and ...
24 Aug 2006 ... GlaxoSmithKline(GSK) and ChemoCentryx Inc. today announced a ... In addition, ChemoCentryx will receive research funding and will be ...
http://www.gsk.com/media/pressreleases/2006/2006_08_24_GSK87...
|
BioCentury - ChemoCentryx Inc. - Company Profile
ChemoCentryx Inc. Completed. 08/24/2006. Venture (Series C financing). $17700000 . ChemoCentryx Inc. Completed. 06/17/2004. Venture (Series B financing) ...
http://www.biocentury.com/companies/ChemoCentryx_Inc?utm_sou...
|
BioPortfolio - ChemoCentryx, Inc.
16 Oct 2008 ... ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
ChemoCentryx, Inc. Cancels IPO - News, Search Jobs, Events
17 Nov 2008 ... PeHUB -- ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and ...
http://www.biospace.com/news_story.aspx?NewsEntityId=117701...
|
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor ...
26 Sep 2007 ... CXCR7 is a novel chemokine receptor whose function was discovered and characterized by ChemoCentryx. ChemoCentryx scientists, joined by ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
ChemoCentryx Advances Second Orally Available CCR9 Antagonist ...
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development. - MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ ...
http://biz.yahoo.com/prnews/081015/aqw521a.html?.v=1...
|
Chemocentryx
08:30 ET, ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III ... 08: 00 ET, ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 ...
http://www.prnewswire.com/gh/cnoc/comp/156506.html...
|
BioPortfolio - ChemoCentryx, Inc. - Profile
View the current ChemoCentryx, Inc. Page on BioPortfolio.com ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available ...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline ...
The milestone payment was triggered by the acceptance of ChemoCentryx' orally bioavailable small molecule, CCX354, as a candidate for full development. ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...
|
|
